CN108904564A - The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii - Google Patents
The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii Download PDFInfo
- Publication number
- CN108904564A CN108904564A CN201810873289.6A CN201810873289A CN108904564A CN 108904564 A CN108904564 A CN 108904564A CN 201810873289 A CN201810873289 A CN 201810873289A CN 108904564 A CN108904564 A CN 108904564A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- geshanxiao
- functional dyspepsia
- extract
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000006549 dyspepsia Diseases 0.000 title description 18
- 238000002360 preparation method Methods 0.000 title description 6
- 241000331432 Cynanchum wilfordii Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 239000003814 drug Substances 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 101150086731 ges-1 gene Proteins 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000028057 Cynanchum auriculatum Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000237786 Lathyrus tuberosus Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004675 intestinal mucosal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了隔山消抗功能性消化不良活性组分分离方法及应用,制备方法是取隔山消药材粗粉用70%乙醇回流提取3次,滤液合并回收乙醇并浓缩至无醇味,以D101大孔树脂吸附,用60%乙醇洗脱,洗脱液回收乙醇并浓缩至浸膏,得到D10160%乙醇段作为隔山消抗功能性消化不良活性组分。本发明筛选出了隔山消抗功能性消化不良的活性组分为隔山消D101 60%乙醇段提取物,从而提供了隔山消在药物上的一种应用,使其可以在医药领域获得推广,帮助治疗诸如功能性消化不良等症状。The invention discloses a method for separating active components of Geshanxiao anti-functional dyspepsia and its application. The preparation method is to extract the coarse powder of Geshanxiao medicinal material with 70% ethanol under reflux for three times, and the filtrate is combined to recover ethanol and concentrated until it has no alcohol smell. Adsorbed on 101 macroporous resin, eluted with 60% ethanol, recovered ethanol from the eluent and concentrated to extract, and obtained D 101 60% ethanol segment as Geshanxiao anti-functional dyspepsia active component. The present invention screens out that the active component of Geshanxiao against functional dyspepsia is the extract of Geshanxiao D101 60% ethanol segment, thereby providing an application of Geshanxiao in medicine, so that it can be promoted in the field of medicine and help Treat symptoms such as functional dyspepsia.
Description
技术领域technical field
本发明涉及一种隔山消抗功能性消化不良活性组分制备方法及应用,属于医药技术领域。The invention relates to a preparation method and application of Geshanxiaokang functional dyspepsia active components, belonging to the technical field of medicine.
技术背景technical background
隔山消为萝摩科白前属植物耳叶牛皮消Cynanchum auriculatumRoyle.et.Wight的块状根(苗药名:窝簸偷vob bex teb),又名飞来鹤、过山消等。始载于《本草纲目》,收载于2003版《贵州省中药、民族药质量标准》、《中华本草》、《贵阳民间药草》等。为贵州少数民族常用药材,民间常用于治疗厌食、肠炎、红白痢疾、消化不良等消化系统疾病。现代药理研究表明隔山消具有抗功能性消化不良、慢性萎缩性胃炎、肠易激综合症等功效。Geshanxiao is the lumpy root of Cynanchum auriculatum Royle.et.Wight (Miao medicine name: vob bex teb), also known as Feilaihe, Guoshanxiao, etc. It was first recorded in "Compendium of Materia Medica", and included in the 2003 edition of "Quality Standards for Traditional Chinese Medicine and Ethnic Medicine in Guizhou Province", "Chinese Materia Medica", "Guiyang Folk Medicinal Herbs", etc. It is a commonly used medicinal material for ethnic minorities in Guizhou. It is commonly used by folks to treat digestive system diseases such as anorexia, enteritis, red and white dysentery, and indigestion. Modern pharmacological studies have shown that Geshanxiao has anti-functional dyspepsia, chronic atrophic gastritis, irritable bowel syndrome and other effects.
功能性消化不良(functional dyspepsia,FD)为一种常见病,多发病,复发率高,且其发病机制尚不明确。据统计显示,我国FD人群发病率达18%~45%,占消化门诊的20%~40%。随着近年胃肠病学的研究进展,人们逐渐意识到的胃肠功能性疾病与许多因素如内脏敏感性的改变、炎症功能的改变以及中枢神经系统和肠神经系统调节功能的变化相关。研究发现FD患者普遍存在胃肠功能障碍和胃肠道黏膜炎症,比利时胃肠道紊乱转化研究中心的Jan Tack教授等认为肠粘膜通透性增强也可能导致炎症及FD。隔山消作为贵州省治疗消化不良的常用药材,具有悠久的药用历史。据国内外文献报道,隔山消类产品或药材总提物具有抗抑郁、抗功能性消化不良、抗肿瘤等功效,其化学成分主要为甾体苷类、苯乙酮类、木脂素类、香豆素类、有机酸类等。目前关于隔山消化学成分的药理活性研究,除了报道21甾体皂苷类成分可能具有抗抑郁、抗肿瘤的作用外,其他药理活性的物质基础尚不明确。目前临床上所用含隔山消的药物大部分仅为复方或较粗糙的制剂,缺乏活性组分和有效成分的开发利用,缺乏客观、科学的隔山消质量控制指标,难以保证隔山消相关产品的临床疗效。Functional dyspepsia (FD) is a common disease with frequent occurrence and high recurrence rate, and its pathogenesis is still unclear. According to statistics, the incidence rate of FD population in my country is 18% to 45%, accounting for 20% to 40% of digestive outpatient clinics. With the progress of gastroenterology research in recent years, people have gradually realized that gastrointestinal functional diseases are related to many factors such as changes in visceral sensitivity, changes in inflammatory functions, and changes in the regulatory functions of the central nervous system and enteric nervous system. Studies have found that gastrointestinal dysfunction and gastrointestinal mucosal inflammation are common in FD patients. Professor Jan Tack from the Translational Research Center for Gastrointestinal Disorders in Belgium believes that increased intestinal mucosal permeability may also lead to inflammation and FD. As a commonly used medicinal material for treating indigestion in Guizhou Province, Geshanxiao has a long history of medicinal use. According to domestic and foreign literature reports, Geshanxiao products or total extracts of medicinal materials have anti-depressant, anti-functional dyspepsia, anti-tumor effects, and its chemical components are mainly steroidal glycosides, acetophenones, lignans, Coumarins, organic acids, etc. The current study on the pharmacological activity of Geshan's digestive components, except that 21 steroidal saponins may have antidepressant and antitumor effects, the material basis of other pharmacological activities is still unclear. At present, most of the medicines containing Geshanxiao used clinically are only compound or relatively rough preparations, lacking the development and utilization of active components and active ingredients, lacking objective and scientific quality control indicators of Geshanxiao, and it is difficult to guarantee the clinical application of Geshanxiao related products. curative effect.
发明内容Contents of the invention
本发明的目的是提供一种隔山消抗功能性消化不良活性组分制备方法及应用。The purpose of the present invention is to provide a preparation method and application of Geshanxiao anti-functional dyspepsia active components.
本发明的技术方案如下:Technical scheme of the present invention is as follows:
一种隔山消抗功能性消化不良活性组分制备方法包括如下步骤:取隔山消药材粗粉用70%乙醇回流提取3次,滤液合并回收乙醇并浓缩至无醇味,以D101大孔树脂吸附,用60%乙醇洗脱,洗脱液回收乙醇并浓缩至浸膏,得到D10160%乙醇段作为隔山消抗功能性消化不良活性组分。A method for preparing Geshanxiao anti-functional dyspepsia active components comprises the following steps: take Geshanxiao medicinal material coarse powder and reflux extract it with 70% ethanol for 3 times, combine the filtrate to recover ethanol and concentrate until it has no alcohol smell, and use D 101 macroporous resin Adsorbed, eluted with 60% ethanol, recovered ethanol from the eluate and concentrated to the extract to obtain D 101 60% ethanol segment as Geshanxiao anti-functional dyspepsia active component.
其中,前述的用70%乙醇回流提取3次包括如下步骤:第一次加入8倍量70%乙醇回流1.5h,第二次、第三次分别加入6倍量70%乙醇回流1h。Wherein, the aforementioned reflux extraction with 70% ethanol for 3 times includes the following steps: adding 8 times the amount of 70% ethanol for the first time and refluxing for 1.5 hours, adding 6 times the amount of 70% ethanol for the second and third times and refluxing for 1 hour respectively.
本发明还提出上述方法筛选的活性组分在制备治疗功能性消化不良的药物中的应用。The present invention also proposes the application of the active components screened by the above method in the preparation of medicaments for treating functional dyspepsia.
本发明筛选出了隔山消抗功能性消化不良的活性组分为隔山消D10160%乙醇段提取物,从而提供了隔山消在药物上的一种应用,使其可以在医药领域获得推广,帮助治疗诸如功能性消化不良等症状。The present invention screens out that the active component of Geshanxiao against functional dyspepsia is the extract of Geshanxiao D10160% ethanol segment, thereby providing an application of Geshanxiao in medicine, so that it can be popularized in the field of medicine and help to treat Symptoms such as functional dyspepsia.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步的详细说明。The present invention will be described in further detail below in conjunction with embodiment.
实施例1:Example 1:
(1)隔山消组分的制备(1) Preparation of Geshanxiao components
取隔山消药材粗粉5Kg用70%乙醇回流提取3次,每次3.5小时,第一次加入8倍量70%乙醇回流1.5h,第二次、第三次分别加入6倍量70%乙醇回流1h,滤液合并回收乙醇并浓缩至无醇味,以D101大孔树脂吸附,依次用水,60%乙醇,85%乙醇洗脱,洗脱液回收乙醇并浓缩至浸膏,得到4个组分:70%乙醇提取物A,D101水段B,D10160%乙醇段C,D10185%乙醇段D。Take 5Kg of Geshanxiao medicinal material coarse powder and extract with 70% ethanol under reflux for 3 times, each time for 3.5 hours, add 8 times the amount of 70% ethanol for the first time and reflux for 1.5 hours, add 6 times the amount of 70% ethanol for the second and third times respectively Reflux for 1 hour, the filtrate was combined to recover ethanol and concentrated to no alcohol smell, adsorbed with D 101 macroporous resin, eluted with water, 60% ethanol, and 85% ethanol in sequence, recovered ethanol from the eluate and concentrated to extract, and obtained 4 groups Divide: 70% ethanol extract A, D 101 water segment B, D 101 60% ethanol segment C, D 101 85% ethanol segment D.
(2)隔山消抗功能性消化不良活性组分的筛选(2) Screening of active components of Geshanxiao against functional dyspepsia
实验分别取隔山消组分(70%乙醇提取物A,D101水段B,D10160%乙醇段C,D10185%乙醇段D)进行小肠推进作用研究、抗炎作用研究。In the experiment, Geshanxiao components (70% ethanol extract A, D 101 water section B, D 101 60% ethanol section C, D 101 85% ethanol section D) were used to study the small intestine propulsion and anti-inflammatory effects.
①小肠推进实验①Small intestine propulsion test
A:对正常小鼠小肠推进功能的影响A: Effects on propulsive function of small intestine in normal mice
取SPF级昆明种小鼠60只,雌雄各半,每组10只,随机分为6组:空白对照组(生理盐水),多潘立酮混悬液组(50mg/kg),70%乙醇提取物A,D101水段B,D10160%乙醇段C,D10185%乙醇段D。各组小鼠均按0.2mL/10g连续灌胃给药4d,1次/d,第3天给药后禁食不禁水12h。并于末次给药1h后,分别灌胃给药5%的炭末混悬液(10%阿拉伯胶+5%活性炭)0.2mL/只,30min后,颈椎脱臼处死小鼠,打开腹腔分离肠系膜,剪取上端至幽门,下端至回盲部的肠管,置于桌面上拉直,测量肠管长度“小肠总长度”,从幽门至炭末前沿的距离作为“炭末推进距离”,用下列公式计算炭末推进百分率。(见表1)。Get 60 SPF level Kunming mice, half male and half female, 10 in every group, are randomly divided into 6 groups: blank control group (normal saline), domperidone suspension group (50mg/kg), 70% ethanol extract A , D 101 water segment B, D 101 60% ethanol segment C, D 101 85% ethanol segment D. Mice in each group were administered by intragastric administration at 0.2 mL/10 g continuously for 4 days, once a day, and fasted for 12 hours after administration on the third day. After 1 hour of the last administration, 0.2 mL/mouse of 5% charcoal powder suspension (10% gum arabic+5% activated carbon) was administered by intragastric administration respectively. After 30 minutes, the mice were killed by cervical dislocation, and the abdominal cavity was opened to separate the mesentery. Cut the intestinal tube from the upper end to the pylorus and from the lower end to the ileocecal, place it on the table and straighten it, measure the length of the intestinal tube "total length of the small intestine", and use the following formula to calculate the distance from the pylorus to the leading edge of the end of charcoal Charcoal propulsion percentage. (See Table 1).
炭末推进百分率(%)=炭末推进距离(cm)/小肠总长度(cm)×100%Charcoal powder propulsion percentage (%) = charcoal powder propulsion distance (cm)/total length of small intestine (cm)×100%
表1隔山消活性组分对正常小鼠小肠推进功能的影响(n=10)Table 1 The effect of active components of Geshanxiao on the small intestine propulsion function of normal mice ( n=10)
注:与空白组比较,*p<0.05,**p<0.01Note: Compared with the blank group, *p<0.05,**p<0.01
B:对阿托品所致小肠推进功能障碍的影响B: Effects on small intestinal propulsion dysfunction caused by atropine
取SPF级昆明种小鼠70只,雌雄各半,随机分为7组,每组10只,分别为:空白对照组(生理盐水),模型对照组,多潘立酮混悬液组(50mg/kg)和70%乙醇提取物A,D101水段B,D10160%乙醇段C,D10185%乙醇段D。灌胃给药1次/d,连续4d。末次给药前禁食不禁水12h,给药30min后,除空白对照组外,其余5组腹腔注射硫酸阿托品0.5mg/kg,10min后分别灌胃给予新鲜配制的炭末混悬液(10%阿拉伯胶+5%活性炭)0.2mL/只,20min后颈椎脱臼处死小鼠,取出小肠铺平,测量小肠全长与炭末混悬液从幽门括约肌推至小肠末端的距离,同上法计算。(见表2)。Get 70 SPF grade Kunming mice, half male and half male, and are randomly divided into 7 groups, 10 in every group, respectively: blank control group (normal saline), model control group, domperidone suspension group (50mg/kg) And 70% ethanol extract A, D 101 water segment B, D 101 60% ethanol segment C, D 101 85% ethanol segment D. Oral administration once a day for 4 consecutive days. Before the last administration, fasting and involuntary water 12h, after administration 30min, except blank control group, all the other 5 groups were intraperitoneally injected atropine sulfate 0.5mg/kg, gavage gave freshly prepared charcoal powder suspension (10% Gum Arabic + 5% activated charcoal) 0.2mL/mouse, the mice were killed by cervical dislocation 20 minutes later, the small intestine was taken out and flattened, and the distance between the full length of the small intestine and the distance from the pyloric sphincter to the end of the small intestine was measured and calculated by the same method as above. (See Table 2).
表2隔山消活性组分对阿托品所致小肠推进功能障碍的影响(n=10)Table 2 The effect of active components of Geshanxiao on small intestinal propulsion dysfunction caused by atropine ( n=10)
注:与空白组比较,*p<0.05,**p<0.01Note: Compared with the blank group, *p<0.05,**p<0.01
②毛细血管通透性实验② Capillary permeability test
取KM小鼠60只,雌雄各半,体重18~22g,随机分为对照组(生理盐水)、阳性药物组、70%乙醇提取物组、D101水段组、D10160%乙醇段、D10185%乙醇段,每组10只。灌胃给药,每天2次,连续给药3天,各组末次给药后1h,尾静脉注射0.5%伊文思蓝生理盐水溶液10ml/kg,随即腹腔注射0.6%醋酸0.2ml/只。20分钟后将小鼠处死,剪开腹壁,用6ml生理盐水分数次冲洗腹腔,收集合并冲洗液,加入生理盐水定容至10ml。3000rpm离心15min,取上清液,于590nm处测定上清液的吸光度,进行统计学处理,求取抑制率(抑制率(%)=(空白组吸光度-给药组吸光度)/空白组吸光度×100%)(见表3)。Get 60 KM mice, half male and half female, body weight 18-22g, randomly divided into control group (normal saline), positive drug group, 70% ethanol extract group, D 101 water section group, D 101 60% ethanol section, D 101 85% ethanol segment, 10 rats in each group. Oral administration, 2 times a day, continuous administration for 3 days, 1 hour after the last administration in each group, 0.5% Evans blue normal saline solution 10ml/kg was injected into the tail vein, followed by intraperitoneal injection of 0.6% acetic acid 0.2ml/rat. After 20 minutes, the mice were sacrificed, the abdominal wall was cut open, and the peritoneal cavity was washed several times with 6 ml of normal saline, the combined washing fluid was collected, and the volume was adjusted to 10 ml by adding normal saline. Centrifuge at 3000rpm for 15min, take the supernatant, measure the absorbance of the supernatant at 590nm, carry out statistical processing, and obtain the inhibition rate (inhibition rate (%)=(absorbance of blank group-absorbance of drug administration group)/absorbance of blank group× 100%) (see Table 3).
表3对醋酸所致小鼠腹腔毛细血管通透性增加的抑制作用(n=10)The inhibitory effect of table 3 on the increase of mouse peritoneal capillary permeability caused by acetic acid ( n=10)
注:与空白组比较,*p<0.05,**p<0.01Note: Compared with the blank group, *p<0.05,**p<0.01
③抗炎活性研究(阿司匹林诱导胃黏膜上皮细胞GES-1损伤模型)③ Anti-inflammatory activity study (aspirin-induced gastric mucosal epithelial cell GES-1 injury model)
A:隔山消各组分对GES-1细胞毒性考察A: Toxicity of each component of Geshanxiao to GES-1 cells
实验结果显示,70%乙醇提取物组、D101水段组、D10160%乙醇段、D10185%乙醇段的剂量在不超过1000μg/ml时对GES-1细胞生长无抑制作用(P>0.05),因此,后续的试验中以下部分的这四个组分段均选用不超过1000μg/ml的给药浓度。The experimental results showed that the doses of 70% ethanol extract group, D 101 water group, D 101 60% ethanol segment, and D 101 85% ethanol segment had no inhibitory effect on the growth of GES-1 cells when they were not more than 1000 μg/ml (P >0.05), therefore, in the follow-up experiments, the four groups in the following sections all selected the administration concentration not exceeding 1000 μg/ml.
B:隔山消各组分对阿司匹林诱导GES-1损伤细胞存活率研究B: Study on the survival rate of aspirin-induced GES-1 damaged cells by each component of Geshanxiao
细胞存活率结果表明,与模型组比较,隔山消D10160%乙醇段能不同程度的提高阿司匹林损伤GES-1细胞存活率,其中200-400μg/mL剂量显著提升损伤细胞存活率(P<0.05)(见表4)。The results of cell survival rate showed that compared with the model group, Geshanxiao D 101 60% ethanol segment could improve the survival rate of aspirin-injured GES-1 cells to varying degrees, and the dose of 200-400 μg/mL significantly improved the survival rate of injured cells (P<0.05 ) (see Table 4).
表4不同组分对阿司匹林损伤GES-1细胞存活率(n=3)The different components of table 4 are to aspirin damage GES-1 cell viability ( n=3)
注:*P<0.05,**P<0.01vsAspirin group;##P<0.01vs Con groupNote: *P<0.05, **P<0.01vsAspirin group; ## P<0.01vs Con group
以上所述,仅是本发明较佳示例而已,并非对作任何数据和形式上的限制,凡是依据本发明的技术实质对以上施例所作的任何数据修改、等同变化,均仍属于本发明技术实质范围内。The above is only a preferred example of the present invention, and is not intended to limit any data and form. Any data modification and equivalent changes made to the above embodiments according to the technical essence of the present invention still belong to the technology of the present invention. within a substantial range.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810873289.6A CN108904564A (en) | 2018-08-02 | 2018-08-02 | The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810873289.6A CN108904564A (en) | 2018-08-02 | 2018-08-02 | The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108904564A true CN108904564A (en) | 2018-11-30 |
Family
ID=64394290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810873289.6A Pending CN108904564A (en) | 2018-08-02 | 2018-08-02 | The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108904564A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497251A (en) * | 2016-01-25 | 2016-04-20 | 济南星懿医药技术有限公司 | Medicine composition for treating functional dyspepsia |
-
2018
- 2018-08-02 CN CN201810873289.6A patent/CN108904564A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497251A (en) * | 2016-01-25 | 2016-04-20 | 济南星懿医药技术有限公司 | Medicine composition for treating functional dyspepsia |
Non-Patent Citations (2)
| Title |
|---|
| 张锦等: "从隔山消中制备4种苯乙酮对照品", 《中国药业》 * |
| 董艳平等: "隔山消对功能性消化不良大鼠一氧化氮", 《现代中西医结合杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9023817B2 (en) | Use of albiflorin for anti-depression | |
| CN101293038B (en) | Leaf extract and its preparation method as well as its preparation and use | |
| CN104491751B (en) | A kind of fatty liver for the treatment of merges Chinese medicine composition of hyperlipidemia and preparation method thereof | |
| CN102743424A (en) | Flos chrysanthemi indici effective ingredient and application thereof | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN104887813A (en) | Schisandra chinensis alcohol extract and application thereof to prepare anti-hepatic fibrosis medicine | |
| CN108904564A (en) | The anti-functional dyspepsia FD active component preparation method and application of cynanchum wilfordii | |
| CN117731680A (en) | Pharmaceutical composition for treating infantile diarrhea, and preparation method and application thereof | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN108514568A (en) | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur | |
| CN108129542A (en) | C-3,28,29- tri- replaces oleanane triterpene saponin and its pharmaceutical composition | |
| CN102670865A (en) | Process for extracting active ingredients of American eleutherine rhizome | |
| CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN114767760B (en) | A composition with liver protecting effect | |
| CN102671034A (en) | The Extract of Imperata Rhizome and Its Application | |
| CN111297886A (en) | Application of gentian polysaccharide in preparation of medicine for preventing or treating liver injury diseases | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN101007044A (en) | A medicine composition for treating peptic ulcer, preparing method and use thereof | |
| CN104587196A (en) | Amorphophallus rivieri-Appendiculate Cremastra Pseudobulb granule effective components and uses of the same in preparation of tumor inhibition drugs | |
| CN115990185B (en) | Application of Jinlanggong polysaccharide in the preparation of drugs for the treatment of ulcerative colitis | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN116059205A (en) | Application of Nigella alkaloids in the preparation of medicines for treating ulcerative colitis | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng | |
| CN101167830A (en) | A kind of anti-ulcerative colitis effective part composition and its preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181130 |